Kindeva, a global contract development and manufacturing organization (CDMO) and drug delivery innovator, has appointed David Stevens, most recently President at Kindeva, as CEO.

With a track record of successfully building and leading teams through significant growth and capacity expansion, Stevens’ appointment aims to ensure Kindeva continues to advance innovation and customer partnerships that improve patient outcomes.

As part of this transition, Milton Boyer has stepped down from his role as Chief Executive Officer. Milton will continue to serve as an independent member of the Board of Directors, providing strategic guidance and continuity.

“I am deeply honored to have the opportunity to succeed Milton as Kindeva’s Chief Executive Officer and look forward to building on his success. Kindeva’s unique heritage of innovation, industry leading capabilities, and our dedicated expert employees, means we have an exciting future ahead,” said David Stevens. “Our focus remains on driving growth and performance by offering best-in-class drug delivery solutions while continuing to provide exceptional service and reliability for our customers. I feel incredibly privileged to lead Kindeva into this next chapter and work alongside our talented team to achieve our ambitious goals.”